Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.65 |
| ▸ | AURKA | O14965 | 6/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944823 | 0.90 | BACE1 (0.66) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7942219 | 0.88 | BACE1 (0.60) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7941938 | 0.88 | BACE1 (0.49) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7935460 | 0.88 | BACE1 (0.49) | BACE1AURKAAURKB | |
| SCHEMBL7942215 | 0.86 | BACE1 (0.61) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7932681 | 0.85 | BACE1 (0.78) | BACE1AURKAAURKBRPS6KB1MAPT | |
| SCHEMBL7942381 | 0.85 | BACE1 (0.56) | BACE1AURKAAURKBRPS6KB1MAPT | |
| SCHEMBL7933178 | 0.84 | BACE1 (0.56) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7943387 | 0.84 | BACE1 (0.75) | BACE1AURKAAURKBRPS6KB1ATR | |
| SCHEMBL7940344 | 0.83 | BACE1 (0.69) | BACE1AURKAAURKBRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885AURKA 3552/4885AURKB 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.